
Opinion|Videos|December 2, 2024
Dosing Frequency and Formulary Decisions for Bispecific Antibodies
Key Takeaways
- Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
- Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
Panelists discuss how when selecting between weekly and biweekly dosing schedules for talquetamab and teclistamab in multiple myeloma treatment, health care institutions must carefully weigh factors like patient convenience, monitoring requirements, resource utilization, and total cost of care alongside clinical outcomes to determine optimal treatment pathways for both patient and health system benefits.
Advertisement
Episodes in this series

Video content above is prompted by the following
- Specifically, for talquetamab and teclistamab, how has your institution standardized selection of weekly or biweekly dosing, and how do these different dosing frequencies differ in terms of impact on the health system and patient?
- What additional factors should be considered when making formulary decisions regarding the 3 currently available bispecific antibodies?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
3
FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5
















































































































































































































